Isentress (Raltegravir Potassium) Patent Expiration, LOE Window & CMS Spending
Isentress (Raltegravir Potassium) by Merck & Co.: FDA Orange Book core substance LOE 2030-06-02 (last listed 2032-03-30), 2 AB generics, $147.0M 2024 CMS Part D & Medicaid spend, and $1,611 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Merck & Co. |
| FDA Application & Pathway | N022145 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2030-06-02 |
| Last Listed Patent or Exclusivity Date | 2032-03-30 |
| Orange Book Patents (*PED Extensions) | 7 patents (2 *PED) |
| Active AB-Rated Generic Competitors | 2 |
| 2024 CMS Total Public Spend | $147.0M |
| 2024 Medicare Part D Spend | $112.7M |
| 2024 Medicaid Spend | $34.3M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($1,611 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.